Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro

被引：25

作者：

Choi, Woo Hee ^{[1
]}

Um, Yoo Hyun ^{[2
]}

Jung, Won Sang ^{[1
]}

Kim, Sung Hoon ^{[3
]}

机构：

[1] Catholic Univ Korea, St Vincents Hosp, Dept Radiol, Coll Med, Suwon, South Korea

[2] Catholic Univ Korea, St Vincents Hosp, Dept Psychiat, Coll Med, Suwon, South Korea

[3] Catholic Univ Korea, Seoul St Marys Hosp, Dept Radiol, Coll Med, 222 Banpodaero, Seoul 137701, South Korea

来源：

ANNALS OF NUCLEAR MEDICINE | 2016年 / 30卷 / 10期

关键词：

Quantification; Florbetaben; PET; beta-Amyloid; Alzheimer's disease; MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND-B; VOLUME EFFECT CORRECTION; FLORBETAPIR F 18; ALZHEIMERS-DISEASE; QUANTITATIVE-ANALYSIS; IN-VIVO; PET; BRAIN; F-18-FLORBETABEN;

D O I：

10.1007/s12149-016-1115-6

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The aim of this study was to examine and compare two automated quantitative software tools (PMOD and MIMneuro) for the quantification of amyloid positron emission tomography (PET). A total of 30 subjects-15 Alzheimer's disease (AD) patients and 15 cognitively normal age- and sex-matched controls-were enrolled. All subjects underwent structural volumetric magnetic resonance imaging (MRI) and amyloid PET scans with F-18 florbetaben. Regional standardized uptake value ratios (SUVRs) using the cerebellar cortex as a reference region were obtained using PMOD and MIMneuro. The SUVRs using both PMOD and MIMneuro showed high discriminatory power between the AD patients and cognitively normal controls. While PMOD and MIMneuro yielded significantly different SUVRs in some brain regions, the two methods had good overall agreement. MIMneuro provides comparable performance to PMOD without the need to acquire brain MRI. Therefore, MIMneuro might be suitable for clinical use to determine amyloid positivity.

引用

页码：682 / 689

页数：8

共 40 条

[1]

[Anonymous], J NUCL MED

[2]

[Anonymous], 2013, J NUCL MED, V54, p10N

[3] Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study [J].